References
- Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541–1552. doi:10.1056/NEJMra1400972.
- Raetz EA, Borowitz MJ, Devidas M, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: a children's oncology group study. J Clin Oncol. 2008;26(24):3971–3978. doi:10.1200/JCO.2008.16.1414.
- Raetz EA, Cairo MS, Borowitz MJ, et al. Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2. Pediatr Blood Cancer. 2015;62(7):1171–1175. doi:10.1002/pbc.25454.
- Eapen M, Raetz E, Zhang MJ, et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood. 2006;107:4961–4967. doi:10.1182/blood-2005-12-4942.
- Eapen M, Zhang MJ, Devidas M, et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with acute lymphoblastic leukemia in a second remission after an isolated central nervous system relapse: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Leukemia. 2008;22:281–286. doi:10.1038/sj.leu.2405037.
- Mody R, Li S, Dover DC, et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the childhood cancer survivor study. Blood. 2008;111(12):5515–5523. doi:10.1182/blood-2007-10-117150.
- Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517. doi:10.1056/NEJMoa1407222.
- Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448. doi:10.1056/NEJMoa1709866.
- Cho YJ, Ahn BY, Lee NG, et al. A combination of E. coli DNA fragments and modified lipopolysaccharides as a cancer immunotherapy. Vaccine. 2006;24(31–32):5862–5871. doi:10.1016/j.vaccine.2006.04.048.
- Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov. 2010;9(4):293–307. doi:10.1038/nrd3203.
- Reid GS, She K, Terrett L, et al. CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response. Blood. 2005;105(9):3641–3647. doi:10.1182/blood-2004-06-2468.
- Allen CE, Laetsch TW, Mody R, et al. Target and agent prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial. J Natl Cancer Inst. 2017;109:djw274.
- Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346(9):645–652. doi:10.1056/NEJMoa011573.
- Arico M, Schrappe M, Hunger SP, et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol. 2010;28:4755–4761. doi:10.1200/JCO.2010.30.1325.
- Schultz KR, Devidas M, Bowman WP, et al. Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from children's oncology group study AALL0031. Leukemia. 2014;28(4):964–967. doi:10.1038/leu.2014.29.
- Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: children's oncology group study AALL0031. Leukemia. 2014;28(7):1467–1471. doi:10.1038/leu.2014.30.